SCHEMBL319857

SCHEMBL319857

CC(C)(C)N(CCO)C(=O)O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
HTT P42858 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAPT P10636 1/20 0.33
PYGL P06737 1/20 0.31
LMNA P02545 3/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31
CYP2C19 P33261 1/20 0.31
SCN1A P35498 1/20 0.31
HIF1A Q16665 1/20 0.31
SCN2A Q99250 1/20 0.31
SCN3A Q9NY46 1/20 0.31
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
MLYCD O95822 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydroxyamine SCHEMBL30884523 0.95 MEN1 (0.33) MEN1KMT2AHTTL3MBTL1MAPT
SCHEMBL790160 0.86 MEN1 (0.33) MEN1KMT2AHTTL3MBTL1
SCHEMBL23117103 0.85 MAPT (0.32) MEN1KMT2AHTTL3MBTL1MAPT
SCHEMBL360638 0.84 GPR84 (0.34) MEN1KMT2AHTTL3MBTL1MLYCD
SCHEMBL15263236 0.82 FFAR1 (0.38) MEN1KMT2AHTTL3MBTL1LMNA
SCHEMBL11060568 0.82 FFAR1 (0.38) MEN1KMT2AHTTL3MBTL1LMNA
SCHEMBL30586107 0.82 CHRNB2 (0.39) LMNAALOX15TSHRCYP2C19
SCHEMBL332512 0.80 CA12 (0.36) MEN1KMT2AHTTL3MBTL1LMNA
SCHEMBL14508469 0.80 MAPT (0.33) MAPTPYGL
SCHEMBL361520 0.79 TSHR (0.39) MEN1KMT2AHTTL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 US disclosed
US-12435066-B2 Substituted tricyclic compounds LUPIN LIMITED (IN) 2025-10-07 US disclosed
US-20250092016-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES NOVARTIS AG (CH) 2025-03-20 US disclosed
US-20250025443-A1 COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES Clear Creek Bio, Inc. (US) 2025-01-23 US disclosed
US-20240391948-A1 NOVEL COMPOUND THAT INHIBITS TNF-ALPHA GENERATION AND INFLAMMASOME ACTIVITY AND PREPARATION METHOD THEREFOR SHAPERON INC. (KR) 2024-11-28 US disclosed
US-20240366608-A1 PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER LUPIN LIMITED (IN) 2024-11-07 US disclosed
US-20240209008-A1 METHOD FOR PRODUCING ASYMMETRIC PHOSPHORIC ACID TRIESTER, METHOD FOR PRODUCING SYMMETRIC PHOSPHORIC ACID TRIESTER, METHOD FOR PRODUCING PHOSPHORIC ACID ESTER, AND METHOD FOR PRODUCING ORGANOPHOSPHORUS COMPOUND TOKYO INSTITUTE OF TECHNOLOGY (JP) 2024-06-27 US disclosed
EP-4378946-A1 NOVEL COMPOUND THAT INHIBITS TNF-A GENERATION AND INFLAMMASOME ACTIVITY AND PREPARATION METHOD THEREFOR Shaperon Inc. (KR) 2024-06-05 EP disclosed
US-11938233-B2 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof UNIVERSITÄTSKLINIKUM REGENSBURG (DE) 2024-03-26 US disclosed
EP-4065575-B1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LTD (IN) 2024-01-31 EP disclosed
WO-2004094363-A1 MUSCARINIC AGONISTS ELI LILLY AND COMPANY (US) 2004-11-04 WO disclosed
US-20040220404-A1 Pyrimidinones as melanin concentrating hormone receptor 1 SMITHKLINE BEECHAM P.L.C. (GB) 2004-11-04 US disclosed
EP-1442025-A1 PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 SMITHKLINE BEECHAM PLC (GB) 2004-08-04 EP disclosed
EP-1406628-A1 TETRAHYDROQUINOLINE DERIVATIVES Akzo Nobel N.V. (NL) 2004-04-14 EP disclosed
WO-2004012816-A1 ANTIBACTERIAL ESTER MACROCYCLES BAYER HEALTHCARE AG (DE) 2004-02-12 WO disclosed
WO-2003033476-A1 PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 SMITHKLINE BEECHAM PLC (GB) 2003-04-24 WO disclosed
WO-2003004028-A1 TETRAHYDROQUINOLINE DERIVATIVES AKZO NOBEL N.V. (NL) 2003-01-16 WO disclosed
WO-2000047693-A9 LUMINESCENT METAL-LIGAND COMPLEXES LJL BIOSYSTEMS INC (US) 2002-04-11 WO disclosed
US-20010021514-A1 Luminescent metal-ligand complexes LJL BIOSYSTEMS, INC. 2001-09-13 US disclosed
WO-2000047693-A1 LUMINESCENT METAL-LIGAND COMPLEXES LJL BIOSYSTEMS, INC. (US) 2000-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885HTT 2464/4885
US-20240366608-A1 PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER NRAS, KRAS, PRMT1 MEN1 625/4885KMT2A 157/4885HTT 2051/4885
US-20240391948-A1 NOVEL COMPOUND THAT INHIBITS TNF-ALPHA GENERATION AND INFLAMMASOME ACTIVITY AND PREPARATION METHOD THEREFOR TNF, IL1B, IL1A MEN1 3375/4885KMT2A 4713/4885HTT 4061/4885
US-20250092016-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES ACE2, ACE, TMPRSS2 MEN1 3749/4885KMT2A 3265/4885HTT 2442/4885
US-20040220404-A1 Pyrimidinones as melanin concentrating hormone receptor 1 MC1R, MCHR1, MCHR2 MEN1 303/4885KMT2A 3945/4885HTT 813/4885
US-20250025443-A1 COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES ACE, PREP, PEPD MEN1 4188/4885KMT2A 1791/4885HTT 2553/4885
US-20240209008-A1 METHOD FOR PRODUCING ASYMMETRIC PHOSPHORIC ACID TRIESTER, METHOD FOR PRODUCING SYMMETRIC PHOSPHORIC ACID TRIESTER, METHOD FOR PRODUCING PHOSPHORIC ACID ESTER, AND METHOD FOR PRODUCING ORGANOPHOSPHORUS COMPOUND HAO2, PLCB1, PHPT1 MEN1 729/4885KMT2A 4410/4885HTT 1582/4885
US-12435066-B2 Substituted tricyclic compounds SOS1, RSU1, KSR1 MEN1 31/4885KMT2A 4241/4885HTT 3659/4885
US-11938233-B2 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof DHPS, SQLE, CYP51A1 MEN1 612/4885KMT2A 4281/4885HTT 1043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.